Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800090 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL5182292 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29352431 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29908079 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29682425 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29401101 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL27435787 | 0.94 | MDM2 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29694496 | 0.93 | PTPN1 (0.58) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL30929979 | 0.92 | TLR2 (0.49) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL30255589 | 0.92 | TLR2 (0.49) | MDM4TP53TLR2MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-110305042-A | N α-fluorenylmethyloxycarbonyl-N γ-(4,4- dimethyl -2,6- dioxo hexamethylene subunit) ethyl-butyric acid preparation method | 吉尔生化（上海）有限公司 | 2019-10-08 | — | — | CN | claimed |
| EP-0555046-B1 | Method for determination of calcium | ORIENTAL YEAST CO LTD (JP) | 1997-07-30 | — | — | EP | claimed |
| US-5618684-A | CALCIUM ACTIVATED TRANSGLUTAMINASE ACTS ON SUBSTRATE TO GENERATE AMMONIA; CORRELATING AMOUNT OF AMMONIA GENERATED WITH AN AMOUNT OF CALCIUM | ORIENTAL YEAST CO., LTD. (JP) | 1997-04-08 | — | — | US | claimed |
| EP-4659764-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
| EP-4389758-A1 | HUMAN TRANSFERRIN RECEPTOR?BINDING PEPTIDE | PeptiDream Inc. (JP) | 2024-06-26 | — | — | EP | disclosed |
| CN-118063551-A | Polypeptide with pH response antibacterial and enzyme response antioxidant functions and application thereof | 郑州大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-6297232-B1 | TREATMENT OF PLATELET AGGREGATION DISORDERS. | ASTRAZENECA AB (SE) | 2001-10-02 | — | — | US | disclosed |
| EP-0946561-A1 | TRIAZOLO(4,5-D)PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | Astra Pharmaceuticals Limited (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028300-A1 | TRIAZOLO[4,5-D]PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-07-02 | — | — | WO | disclosed |
| US-5639742-A | ANTIBIOTIC; BACTERICIDE | LEE VING JICK (US) | 1997-06-17 | — | — | US | disclosed |
| US-5371076-A | ANTIBIOTICS | AMERICAN CYANAMID COMPANY (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0618190-A1 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0319689-B1 | N-sultam-sulfon amides substituted by a heterocyclic ring, process for their preparation and their use as herbicides and as plant growth regulators | HOECHST AG (DE) | 1993-12-15 | — | — | EP | disclosed |
| EP-0319689-A2 | N-sultam-sulfon amides substituted by a heterocyclic ring, process for their preparation and their use as herbicides and as plant growth regulators | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | MDM4 2377/4885TP53 3358/4885TLR2 4722/4885 |
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | MDM4 156/4885TP53 32/4885TLR2 1185/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | MDM4 156/4885TP53 32/4885TLR2 1185/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | MDM4 156/4885TP53 32/4885TLR2 1185/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | MDM4 156/4885TP53 32/4885TLR2 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.